Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status

被引:2
作者
Sousa, Vitor [1 ,2 ]
Rodrigues, Carolina [1 ]
Silva, Maria [1 ]
Alarcao, Ana Maria [1 ]
Carvalho, Lina [1 ,2 ]
机构
[1] Univ Coimbra, Fac Med, Inst Pathol, IAP FMUC, Coimbra, Portugal
[2] Coimbra Univ Hosp, Inst Pathol, Coimbra, Portugal
关键词
Lung; EGFR; KRAS; HER2; Immunohistochemistry; Adenocarcinomas; GROWTH-FACTOR-RECEPTOR; TRANSCRIPTION FACTOR-I; K-RAS MUTATIONS; GEFITINIB SENSITIVITY; SOMATIC MUTATIONS; CELL-CARCINOMA; GENE-MUTATIONS; KINASE DOMAIN; CANCER; EXPRESSION;
D O I
10.1016/j.rppnen.2014.09.009
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Pulmonary adenocarcinomas are still in the process of achieving morphological, immunohistochemical and genetic standardization. The ATS/ERS/IASLC proposed classification for lung adenocarcinomas supports the value of the identification of histological patterns, specifically in biopsies. Thirty pulmonary adenocarcinomas were subjected to immunohistochemical study (CK7, CK5, 6, 18, CK20, TTF1, CD56, HER2, EGFR and Ki-67), FISH and PCR followed by sequencing and fragment analysis for EGFR, HER2 and KRAS. Solid pattern showed lower TTF1 and higher Ki-67 expression. TTF1 expression was higher in non-mucinous lepidic and micropapillary patterns when compared to acinar and solid and acinar, solid and mucinous respectively. Higher Ki67 expression was present in lepidic and solid patterns compared to mucinous. EGFR membranous staining had increasing expression from non-mucinous lepidic/BA pattern to solid pattern and micropapillary until acinar pattern. EGFR mutations, mainly in exon 19, were more frequent in females, together with non-smoking status, while KRAS exon 2 mutations were statistically more frequent in males, especially in solid pattern. FISH EGFR copy was correlated gross, with mutations. HER2 copy number was raised in female tumours without mutations, in all cases. Although EGFR and KRAS mutations are generally considered mutually exclusive, in rare cases they can coexist as it happened in one of this series, and was represented in acinar pattern with rates of 42.9% and 17.9%, respectively. EGFR mutations were more frequent in lepidic/BA and acinar patterns. Some cases showed different EGFR mutations. The differences identified between the adenocarcinoma patterns reinforce the need to carefully identify the patterns present, with implications in diagnosis and in pathogenic understanding. EGFR and KRAS mutational status can be determined in biopsies representing bronchial pulmonary carcinomas because when a mutation is present it is generally present in all the histological patterns. (C) 2014 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:113 / 125
页数:13
相关论文
共 59 条
  • [1] Amann J, 2005, CANCER RES, V65, P226
  • [2] HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer
    Cappuzzo, F
    Bemis, L
    Varella-Garcia, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) : 2619 - 2621
  • [3] Neves Lúcio Roberto de Oliveira das, 2009, Arq. Gastroenterol., V46, P116
  • [4] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    Eberhard, DA
    Johnson, BE
    Amler, LC
    Goddard, AD
    Heldens, SL
    Herbst, RS
    Ince, WL
    Jänne, PA
    Januario, T
    Johnson, DH
    Klein, P
    Miller, VA
    Ostland, MA
    Ramies, DA
    Sebisanovic, D
    Stinson, JA
    Zhang, YR
    Seshagiri, S
    Hillan, KJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5900 - 5909
  • [5] Comparison of FISH, PCR, and Immunohistochemistry in Assessing EGFR Status in Lung Adenocarcinoma and Correlation With Clinicopathologic Features
    El-Zammar, Ola A.
    Zhang, Shengle
    Katzenstein, Anna-Luise A.
    [J]. DIAGNOSTIC MOLECULAR PATHOLOGY, 2009, 18 (03) : 133 - 137
  • [6] Endoh H, 2006, J THORAC ONCOL, V1, P629
  • [7] Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features
    Finberg, Karin E.
    Sequist, Lecia V.
    Joshi, Victoria A.
    Muzikansky, Alona
    Miller, Julie M.
    Han, Moonjoo
    Beheshti, Javad
    Chirieac, Lucian R.
    Mark, Eugene J.
    Iafrate, A. John
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2007, 9 (03) : 320 - 326
  • [8] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    Gazdar, A. F.
    [J]. ONCOGENE, 2009, 28 : S24 - S31
  • [9] Gumerlock PH, 2005, J CLIN ONCOL, V23, p623S
  • [10] Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
    Han, SW
    Kim, TY
    Jeon, YK
    Hwang, PG
    Im, SA
    Lee, KH
    Kim, JH
    Kim, DW
    Heo, DS
    Kim, NK
    Chung, DH
    Bang, YJ
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (08) : 2538 - 2544